Table 2. Factors associated with overall survival in 102 patients with advanced NSCLC according to univariate analysis.
| Characteristic | Median or no. of cases | Median survival time (months)<median vs. ≥median(or left vs. right) | p-value | Chi-square | 95% CI of hazard ratio |
|---|---|---|---|---|---|
| Sex (male-female) | 57-45 | 3.07 vs. 4.23 | 0.0305 | 4.683 | 1.042 to 2.309 |
| Age (year) | 67 | 3.10 vs. 3.27 | 0.5676 | 0.3266 | 0.5887 to 1.337 |
| Weight (kg) | 162 | 3.27 vs. 3.10 | 0.6156 | 0.2520 | 0.6066 to 1.345 |
| Height (cm) | 170 | 3.97 vs. 2.92 | 0.1085 | 2.577 | 0.4759 to 1.077 |
| Smoke history (yes-no) | 71-31 | 3.2 0 vs. 3.10 | 0.7461 | 0.1048 | 0.6018 to 1.439 |
| Pleural effusion (yes-no) | 55-47 | 3.07 vs. 3.27 | 0.6862 | 0.1633 | 0.7309 to 1.610 |
| Tumor size (cm) | 4.35 | 2.93 vs. 3.23 | 0.5509 | 0.3557 | 0.5904 to 1.325 |
| Tumor site (central-peripheral) | 42-60 | 3.08 vs. 3.25 | 0.0451 | 4.013 | 1.009 to 2.375 |
| CEA (ng/mL) | 43.79 | 3.20 vs. 3.09 | 0.2187 | 1.513 | 0.5124 to 1.165 |
| CA125 (u/mL) | 65.99 | 2.85 vs. 3.95 | 0.8087 | 0.0586 | 0.7034 to 1.570 |
| CA153 (u/mL) | 34.39 | 3.47 vs. 3.02 | 0.4449 | 0.5835 | 0.5745 to 1.276 |
| EGFR mutation (yes-no) | 17-31* | 6.13 vs. 3.10 | 0.0381 | 4.298 | 0.2998 to 0.9667 |
| Number of tumor somatic mutations | 3** | 4.27 vs. 2.43 | 0.0451 | 4.017 | 0.2365 to 0.9841 |
| Previous treatments | |||||
| Surgery (yes-no) | 7-95 | 3.10 vs. 3.20 | 0.4324 | 0.6165 | 0.5879 to 3.459 |
| Local radiotherapy (yes-no) | 89-13 | 3.20 vs. 3.10 | 0.7088 | 0.1394 | 0.4807 to 1.646 |
| Chemotherapy (yes-no) | 73-29 | 3.20 vs. 2.93 | 0.5201 | 0.4137 | 0.7518 to 1.758 |
| EGFR inhibitor (yes-no) | 17-31* | 6.13 vs. 3.10 | 0.0381 | 4.298 | 0.2998 to 0.9667 |
| Chemotherapy cycles | 3 | 3.60 vs. 3.10 | 0.3435 | 0.8973 | 0.5440 to 1.236 |
| Lymphocyte (%) | 19.6 | 2.87 vs. 4.01 | 0.0894 | 2.885 | 0.9484 to 2.097 |
| Brain metastases (yes-no) | 11-91 | 2.87 vs. 3.20 | 0.9912 | 0.0001 | 0.5281 to 1.880 |
| Bone metastases (yes-no) | 35-67 | 3.10 vs. 3.20 | 0.8146 | 0.0550 | 0.6287 to 1.440 |
| Metastases (visceral-bone) | 17-35 | 2.93 vs. 3.10 | 0.6422 | 0.3714 | 0.6540 to 2.243 |
| Disease stage (III-IV) | 38-64 | 3.20 vs. 3.10 | 0.6973 | 0.2791 | 0.7367 to 1.701 |
| Tumor histology (SQ-AD)* | 48-54 | 3.00 vs. 3.62 | 0.0205 | 5.367 | 0.4020 to 0.9268 |
| ECOG PS (0/1/2-3) | 31-71 | 4.58 vs. 2.77 | 0.0003 | 13.05 | 0.3125 to 0.7082 |
*
48 of 102 underwent EGFR mutation analysis;
**
40 of 102 patients underwent 508 gene panel analysis (23). SQ, squamous cell carcinoma; AD, adenocarcinoma